Stock Market & Financial Investment News: Educated Investors Get Live Stock Market News Feeds & Alerts at The Fly On the Wall

News For MRK;PFE;GSK;JNJ;BMY;NVS;SHPG;ABT;CELG;SNY From The Last 14 Days Check below for free stories on MRK;PFE;GSK;JNJ;BMY;NVS;SHPG;ABT;CELG;SNY the last two weeks. Sign up for a free trial to see the rest of the stories you've been missing.
<< 1 \| 2 \| 3 \| 4 \| 5 \| all recent news \| >>
May 22, 2013
08:59 EDT	PFE	On The Fly: Pre-market Movers Subscribe for More Information

08:25 EDT	GSK	GlaxoSmithKline awarded up to $200M by U.S. to develop new antibiotics Subscribe for More Information

08:06 EDT	PFE	Zoetis comments on Pfizer’s split-off plans for remaining interest Subscribe for More Information

08:04 EDT	PFE	Pfizer announces plan to split-off remainder of Zoetis Subscribe for More Information

08:02 EDT	PFE	Pfizer announces plan to split-off remainder of Zoetis Subscribe for More Information

07:45 EDT	MRK	FDA Peripheral & Central Nervous System Drugs Advisory Committee holds a meeting Subscribe for More Information

07:28 EDT	ABT	UBS to host a conference Global Healthcare Services Conference is being held in New York on May 20-22 with webcasted company presentations to begin on May 22 at 8 am; not all company presentations may be webcasted. Webcast Link

06:05 EDT	BMY	Bristol-Myers upgraded to Buy from Neutral at Citigroup Subscribe for More Information

May 21, 2013
18:56 EDT	MRK	On The Fly: After Hours Movers Subscribe for More Information

17:03 EDT	MRK	Merck announces $5B share repurchase Subscribe for More Information

17:01 EDT	MRK	Merck announces $5B accelerated share repurchase Subscribe for More Information

08:03 EDT	ABT	Abbott announces CE Mark for coronary drug eluting stent Subscribe for More Information

07:44 EDT	NVS, MRK, SNY, GSK	Sachs Associates to host a forum Subscribe for More Information

07:34 EDT	BMY	UBS to host a conference Subscribe for More Information

07:24 EDT	NVS, BMY, JNJ	Global Health Care to host a conference Subscribe for More Information

07:16 EDT	PFE	Pfizer management to meet with Leerink Subscribe for More Information

07:07 EDT	GSK	Theravance pullback on Elan bid a buying opportunity, says Piper Jaffray Subscribe for More Information

May 20, 2013
17:49 EDT	MRK	Merck sleep drug effective, dosages questioned, WSJ reports Subscribe for More Information

17:26 EDT	SNY	Regeneron, Genentech, Sanofi enter into 'Zaltrap agreement' Subscribe for More Information

17:04 EDT	PFE	Pfizer discontinues phase 3 study of inotuzumab ozogamicin Subscribe for More Information

11:27 EDT	SNY	Appeals court reverses, remands patent ruling in Sanofi suit against Mylan, Teva Subscribe for More Information

10:11 EDT	ABT	On The Fly: Analyst Upgrade Summary Subscribe for More Information

10:03 EDT	SHPG, BMY	Shire advances after report renews takeover speculation Subscribe for More Information

09:51 EDT	CELG	Celgene management to meet with JPMorgan Meetings to be held in Boston on May 22-23 hosted by JPMorgan.

07:32 EDT	MRK	Society for Information Display / IHS to host a conference Display Week 2013 is being held in Vancouver, British Columbia on May 19-24.

07:29 EDT	NVS	Deutsche Bank to host a conference dbAccess Asia Conference 2013 is being held in Singapore on May 20-22.

07:27 EDT	SHPG	American Psychiatric Association to host annual meeting Subscribe for More Information

07:01 EDT	SHPG	Sangamo BioSciences announces positive data for Vivo Protein platform Sangamo BioSciences (SGMO) announced the presentation of new data demonstrating the successful application of Sangamo's proprietary In Vivo Protein Replacement Platform to produce therapeutically relevant levels of Factor VIII in a mouse model. Sangamo has partnered with Shire (SHPG) to develop ZFP Therapeutics for both hemophilia A and B using this approach.

06:30 EDT	SHPG, BMY	Leerink estimates Shire takeout value at least $110 per share Leerink says a takeover price for Shire (SHPG) would need to be at least $110 per share in order to get the company's board to consider a sale. The firm notes a Daily Mail report last night said Bristol-Myers (BMY) has engaged advisors to study an acquisition of Shire and that Shire's CEO has contacted bankers to consider anti-takeover measures. Leerink believes a Bristol-Myers takeover of Shire would make sense and keeps an Outperform rating on Shire.

06:25 EDT	SHPG, BMY	Shire may return cash to thwart takeover, Daily Mail reports Subscribe for More Information

06:01 EDT	ABT	Abbott upgraded to Buy from Neutral at Goldman Goldman upgraded Abbott to reflect accelerating growth driven by emerging markets, better growth and product mix, new product launches, and market share gains. Price target raised to $44 from $38.

May 17, 2013
16:20 EDT	NVS	Novartis drug Afinitor extended time without disease progression in women Subscribe for More Information

13:21 EDT	BMY	Options with increasing implied volatility: CPRT BMY GDI HNZ Subscribe for More Information

08:03 EDT	SNY	Sanofi reports positive topline results from pivotal Phase III Jakarta study Subscribe for More Information

06:19 EDT	JNJ	J&J to end sales of of metal-on-metal hip replacements, Bloomberg reports Subscribe for More Information

05:51 EDT	CELG	Stocks with implied volatility movement; CBST CELG Subscribe for More Information

05:18 EDT	SNY	Sanofi says JAK2 inhibitor for myelofibrosis met primary endpoint Subscribe for More Information

May 16, 2013
16:32 EDT	BMY	Bristol-Myers announces intention to voluntarily delist preferred stock Subscribe for More Information

13:20 EDT	BMY	Follow-up: Bristol-Myers upgraded to Outperform from Market Perform at Leerink Leerink upgraded Bristol-Myers citing the company's multi-billion dollar immuno-oncology prospects. The firm says there were additional responses reported in the press briefing with combination nivolumab and Yervoy. Leerink has a $51 price target for shares.

13:14 EDT	BMY	Bristol-Myers upgraded to Outperform from Market Perform at Leerink Subscribe for More Information

11:50 EDT	CELG	Celgene, Gilead lower after new data published at ASCO Subscribe for More Information

08:55 EDT	BMY, PFE, MRK	BofA/Merrill's pharmaceuticals analysts hold analyst/industry conference call Subscribe for More Information

08:38 EDT	BMY	Bristol-Myers shares likely to give back recent gains, says Leerink Leerink expects shares of Bristol-Myers to give back recent gains after ASCO published abstracts last night. The firm found the abstracts as in-line with, but not above, its expectations for nivolumab alone or immuno-oncology combination therapy and keeps a Market Perform rating on Bristol-Myers.

08:11 EDT	NVS	Novartis says no intention of pursuing Actavis, Bloomberg reports Subscribe for More Information

05:52 EDT	BMY	Stocks with implied volatility movement; BMY SLV Subscribe for More Information

May 15, 2013
19:37 EDT	NVS	Novartis weighing Actavis bid, WSJ reports Subscribe for More Information

18:17 EDT	NVS	Novartis weighs possible bid for Actavis, DJ reports Subscribe for More Information

16:51 EDT	JNJ	FDA approves Simponi to treat ulcerative colitis Subscribe for More Information

15:16 EDT	SNY	Sanofi systemic sclerosis treatment designated for orphan drug status Subscribe for More Information

11:28 EDT	BMY	Options with increasing implied volatility: BMY AGNC EBIX IAU Subscribe for More Information

09:43 EDT	BMY	Active equity option families trading on open Subscribe for More Information

05:39 EDT	SNY	Sanofi, Regeneron announce patient enrollment in two Phase 3 trials Subscribe for More Information

May 14, 2013
17:39 EDT	MRK	Moody's lowers Merck's guaranteed debt to A1 from Aa3; stable outlook Moody's Investors Service lowered the long-term ratings of Merck by one notch, including the guaranteed senior unsecured rating to A1 from Aa3 and the non-guaranteed senior unsecured rating to A2 from A1. This action concludes a review for downgrade initiated on May 1, 2013. At the same time, Moody's affirmed Merck's Prime-1 commercial paper rating. The rating outlook is stable.

07:24 EDT	GSK, BMY, SHPG	EBD Group to host a conference BioTrinity 2013 is being held in Newbury, England on May 14-16.

May 13, 2013
16:25 EDT	GSK	On The Fly: Closing Wrap Stocks on Wall Street were little changed from their opening levels as investors weighed the potential end of the Fed's quantitative easing program against a better than expected report on retail sales. The Wall Street Journal's Jon Hilsenrath suggested in a report over the weekend that the Federal Reserve has mapped a QE exit strategy. The report paired with the retail sales data left the market lacking conviction in either direction today, as the averages spent the majority of the session range-bound near the flatline. ECONOMIC EVENTS: In the U.S., retail sales rose 0.1% in April, which beat expectations for a 0.3% decline. Retail sales excluding autos, gas, and building materials rose 0.6%, which was also better than expected. Business inventories were flat in March, versus expectations for a 0.3% gain. In Asia, Chinese factory output grew 9.3% annually in April, which was up from 8.9% in March but still missed expectations for a 9.5% growth rate. COMPANY NEWS: The Supreme Court ruled unanimously that Monsanto's (MON) patented genetically altered soybeans are protected and that farmers cannot use them to create new seeds without paying the company... Dell's (DELL) special committee publicly asked for more information from Carl Icahn and Southeastern Asset Management about their proposed leveraged recapitalization. This request follows television interviews by Icahn last Friday in which he discussed his Dell proposal, as well as a weekend report in Barron's saying the Icahn and Southeastern plan could be a better deal for shareholders. MAJOR MOVERS: Among the notable gainers was Theravance (THRX), up $6.26, or 17.92%, to $41.20 after Elan Corporation (ELN) bought a stake in the potential future royalty payments from four respiratory programs partnered with GlaxoSmithKline (GSK) in exchange for $1B in cash. Also higher was Tesla (TSLA), which rose $11.04, or 14.38%, to $87.80 in its third straight double-digit percentage gain following a better-than-expected earnings report last week. Among the noteworthy losers was Barnes & Noble (BKS), down $2.21, or 9.48%, to $21.10 after the blog InsiderMonkey disputed a previous report about Microsoft's (MSFT) interest in the bookseller's NOOK assets. Also lower was JoS. A. Bank (JOSB), down $3.31, or 7.16%, to $42.90 after the company's first quarter earnings view came in below expectations. INDICES: The Dow was down 26.81, or 0.18%, to 15,091.68; the Nasdaq was up 2.21, or 0.06%, to 3,438.79; and the S&P 500 was nearly unchanged at 1,633.77.

12:20 EDT	GSK	On The Fly: Midday Wrap Subscribe for More Information

09:44 EDT	SNY	Several companies reportedly interested in buying Adcock Ingram, Globes says Subscribe for More Information

07:30 EDT	SNY	TechConnect to host a summit 2013 National Innovation Summit is being held in Washington, D.C. on May 12-16.

05:44 EDT	GSK	Elan provides additional information on Elan/Theravance agreement Subscribe for More Information

05:35 EDT	GSK	Theravance, Elan enter into $1B royalty participation agreement Subscribe for More Information

May 10, 2013
16:29 EDT	PFE	On The Fly: Closing Wrap Subscribe for More Information

12:42 EDT	GSK	GlaxoSmithKline, Theravance confirm FDA approval of Breo Ellipta Subscribe for More Information

12:31 EDT	PFE	On The Fly: Midday Wrap Subscribe for More Information

11:48 EDT	BMY, GSK, SNY, MRK, JNJ, PFE	Drugmakers to face pressure on U.S. prices, Reuters says Subscribe for More Information

11:15 EDT	GSK	FDA approves Breo Ellipta to treat chronic obstructive pulmonary disease Subscribe for More Information

10:00 EDT	SHPG	On The Fly: Analyst Downgrade Summary Subscribe for More Information

09:21 EDT	PFE	On The Fly: Pre-market Movers Subscribe for More Information

08:08 EDT	PFE	Pain Therapeutics discloses Pfizer reassessing continued Remoxy partnership Pain Therapeutics (PTIE) disclosed a letter its CEO was sent from partner Pfizer (PFE) in which the drug maker said it is reassessing its endorsement of the Remoxy program "given the years of delay, additional cost incurred to bring the program to this point and development work left in the program." Pfizer said it will be reaching out to Pain Therapeutics "shortly" to have a confidential discussion about the terms of the companies' contractual agreement over the pain drug. Pfizer that it appears there is a regulatory pathway forward for Remoxy, but that the company does not expect to respond to submit a Complete Response letter for Remoxy to the FDA before mid-2015. Pfizer added in its letter to Pain Therapeutics "no final decision has been made at this time" on how it will proceed with the Remoxy development program. Shares of Pain Therapeutics fell 47% to $2.81 in pre-market trading following the disclosure of the correspondence.

07:46 EDT	PFE	DURECT says additional clinical studies needed for Remoxy DURECT (DRRX) announced that Pfizer (PFE) has provided an update on Remoxy in a regulatory filing. Pfizer's disclosure included: "We have been working to address the issues raised in the letter, which primarily relate to manufacturing. We met with the FDA in March 2013 to discuss our plan to address the June 2011 "complete response" letter. We received written guidance from the FDA in May regarding required next steps, including additional clinical studies, to address the letter. Based on this guidance, we are considering our options with respect to Remoxy. If we elect to continue development of Remoxy, we would not expect to submit a response to the 'complete response' letter before mid-2015." DURECT said it understands from Pfizer that additional clinical studies are necessary and include, in part, a pivotal bioequivalence study with the modified formulation to bridge to the clinical data conducted with the original formulation, as well as an abuse potential study with the modified Remoxy formulation. Remoxy is based on DURECT's ORADUR technology. Shares of Pfizer's Remoxy partner Pain Therapeutics (PTIE) are down 56% in pre-market trading, while shares of DURECT are down 13%, or 20c, to $1.39.

06:53 EDT	GSK, MRK	GlaxoSmithKline, Merck to discount cancer vaccine in poor nations, NY Times says Subscribe for More Information

06:16 EDT	JNJ	Obesity surgery booming in India, Bloomberg reports Subscribe for More Information

05:42 EDT	SHPG	Shire downgraded to Neutral from Overweight at JPMorgan

05:42 EDT	NVS	Novartis drug Ilaris approved by FDA Subscribe for More Information

May 9, 2013
17:09 EDT	JNJ	Johnson & Johnson deal to settle sales practices probe stalls, WSJ reports Johnson & Johnson's $2.2B settlement with the Justice Department related to its promotion of certain drugs is on hold as the company is looking to avoid language in the agreement that could make it vulnerable to private lawsuits, reports The Wall Street Journal, citing people familiar with the talks. Reference Link

12:24 EDT	SHPG	Shire unit wins patent trial against Watson regarding LIALDA Shire (SHPG), announces that its subsidiary, Shire Development, has prevailed in its litigation against Watson Pharmaceuticals, Watson Laboratories-Florida, Watson Pharma. and Watson Laboratories in connection with their Abbreviated New Drug Application for a generic version of Shire's LIALDA delayed release tablets for the induction of remission in adults with active, mild to moderate ulcerative colitis and for the maintenance of remission of ulcerative colitis. Following a five day bench trial in the Southern District of Florida, Judge Middlebrooks issued a ruling upholding the validity of the patent covering LIALDA, US Patent No. 6,773,720, and holding that the proposed ANDA formulation infringes the claims of that patent. Accordingly, Judge Middlebrooks confirmed that Shire is entitled to an injunction, which he will issue separately, which prohibits the FDA from approving the ANDA formulation until the expiration of the '720 patent.

10:17 EDT	BMY, PFE, SHPG	Shire trades higher in London amid takeover chatter, Guardian says Subscribe for More Information

09:51 EDT	JNJ	J&J unit says first patient enrolled in reMARQable study Subscribe for More Information

07:22 EDT	MRK	Merck awarded significant portion of UNICEF HPV vaccine tender Subscribe for More Information

07:04 EDT	ABT	Abbott announces CE Mark for A1c test Subscribe for More Information

May 8, 2013
10:33 EDT	PFE, BMY	Bristol-Myers, Pfizer announced results from ARISTOTLE trial subanalysis Bristol-Myers (BMY) and Pfizer (PFE) announced yesterday that results from a prespecified subanalysis of the ARISTOTLE trial were published in Circulation, the peer-reviewed journal of the American Heart Association. Results from the subanalysis showed that the reductions in stroke or systemic embolism, number of major bleeding events and mortality demonstrated with Eliquis compared to warfarin in the ARISTOTLE trial were consistent across subgroups defined based on levels of International Normalized Ratio control in patients with nonvalvular atrial fibrillation. This story corrects a headline from yesterday.

08:32 EDT	MRK	Merck says FDA accepts biologics license application for allergy tablet Merck announced that the Biologics License Application for its investigational ragweed pollen sublingual allergy immunotherapy tablet has been accepted for review by the U.S. Food and Drug Administration. The BLA for Merck’s investigational ragweed pollen sublingual allergy immunotherapy tablet is supported by five studies evaluating the efficacy and safety of the tablet in adults, 18 years of age or older, with ragweed induced allergic rhinitis. On March 27, Merck announced that the FDA had also accepted the BLA for its investigational Timothy grass pollen sublingual allergy immunotherapy tablet. Merck expects the FDA’s review for both to be completed in the first half of 2014.

07:38 EDT	JNJ	BofA/Merrill's medical tech analyst hold an analyst/industry conference call Subscribe for More Information

<< 1 \| 2 \| 3 \| 4 \| 5 \| all recent news \| >> Sign up for a free trial to see the rest of the stories you've been missing.